AVTX vs. MBRX, ABVC, ERNA, GHSI, MNPR, VAXX, GRTX, ELAB, AEZS, and KTRA
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Moleculin Biotech (MBRX), ABVC BioPharma (ABVC), Eterna Therapeutics (ERNA), Guardion Health Sciences (GHSI), Monopar Therapeutics (MNPR), Vaxxinity (VAXX), Galera Therapeutics (GRTX), Elevai Labs (ELAB), Aeterna Zentaris (AEZS), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
Moleculin Biotech (NASDAQ:MBRX) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.
15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 6.7% of Moleculin Biotech shares are owned by company insiders. Comparatively, 0.2% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Moleculin Biotech received 222 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 53.16% of users gave Moleculin Biotech an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
Moleculin Biotech has higher earnings, but lower revenue than Avalo Therapeutics.
Moleculin Biotech has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Moleculin Biotech has a net margin of 0.00% compared to Moleculin Biotech's net margin of -1,639.50%. Avalo Therapeutics' return on equity of -87.19% beat Moleculin Biotech's return on equity.
In the previous week, Moleculin Biotech had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 2 mentions for Moleculin Biotech and 0 mentions for Avalo Therapeutics. Moleculin Biotech's average media sentiment score of 1.00 beat Avalo Therapeutics' score of 0.33 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
Moleculin Biotech currently has a consensus target price of $35.00, indicating a potential upside of 591.70%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Moleculin Biotech is more favorable than Avalo Therapeutics.
Summary
Moleculin Biotech beats Avalo Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
